{
  "nctId": "NCT04026750",
  "briefTitle": "Insulin Tolerance Test Study in Patients With Type 1 Diabetes",
  "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Insulin Tolerance Test Study to Assess the Safety, Tolerability, and Pharmacodynamics OF Pitolisant in Patients With Type 1 Diabetes",
  "protocolDocument": {
    "nctId": "NCT04026750",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-12-13",
    "uploadDate": "2021-03-09T11:10",
    "size": 778060,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04026750/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 5,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-09-15",
    "completionDate": "2020-02-16",
    "primaryCompletionDate": "2020-02-16",
    "firstSubmitDate": "2019-07-17",
    "firstPostDate": "2019-07-19"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Inclusion criteria: Diagnosis of diabetes =\\> 4yrs, On Insulin =\\> 4yrs, HbA1c\\<= 10%, At least one episode of severe hypoglycemia in past 12 months, fasting c-peptide \\<0.7 ng/ml\n\nExclusion Criteria:\n\n* Hypoglycemia unawareness, DKA within 3 months prior to randomization, Reduced renal function, Anxiety and depression",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change From Baseline in Peak Glucagon Response to Hypoglycemia",
        "description": "Change in peak glucagon concentration from day 1 ITT (baseline) to day 7 ITT (on treatment). Serial glucagon collected during ITT's, occurred at -10, 0, 15, 30, 45, 60, 90, 120 and 180 minutes just prior to and during the ITT.",
        "timeFrame": "Change in peak glucagon during ITT Day 1 vs. Day 7"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Patients Returning to Blood Glucose =>70 mg/dL",
        "description": "Number of patients that returned to blood glucose =\\>70 mg/dL during ITT",
        "timeFrame": "Day 7"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:08.899Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}